Insight on Pharmaceuticals and Healthcare

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Report
Report

Myelodysplastic Syndrome: An Underserved Population Offers Commercial Opportunity

SuperGen/MGI Pharma's Dacogen and Celgene's Revlimid are in pre-registration for treatment of myelodysplastic syndrome (MDS). However, a significant proportion of the MDS population will be left underserved by pharmacotherapy.

Published By Datamonitor
18 Oct 2005 $1900
Buy
Report
Report

Pipeline Insight: Small Molecule Targeted Cancer Therapies - New targets set to drive growth

Overview of the current small molecule targeted therapies pipeline in oncology, including analysis of late-phase products, clinical trial data, sales forecasts through to 2019, Datamonitor drug assessment summaries and key opinion leader insight.

Published By Datamonitor
14 Apr 2010 $11400
Buy
Report
Report

Stakeholder Opinions: Respiratory viral infections - Respiratory syncytial virus, parainfluenza virus and human metapneumovirus as promising new targets

This report discusses the market opportunity for respiratory antivirals in the seven major markets (7MM). It outlines patient and sales data, provides an analysis of marketed and pipeline drugs, and discusses opportunities and threats in this sector.

Published By Datamonitor
29 Apr 2010 $3800
Buy
Report
Report

Pipeline Insight: Epilepsy - Past successes hard to emulate in highly genericized market

In-depth analysis of the epilepsy drug pipeline, including assessment of the clinical and commercial prospects of late-stage agents, unmet market needs, sales forecasts to 2019, and key opinion leader insight.

Published By Datamonitor
12 May 2010 $11400
Buy

Order this report by the 10th September 2010 and receive a 15% discount

To take advantage of this offer enter Promo Code opioid15 when prompted in the checkout

More information

Report
Report

Commercial Insight: Opioids in Australia

In-depth overview and 10 year outlook for currently marketed and pipeline opioid products in Australia, examining both clinical and commercial factors driving product differentiation and uptake.

Published By Datamonitor
20 May 2010 $5700
Buy
Report
Report

Commercial Insight: Asthma/COPD in Australia

In-depth overview and 10 year outlook for currently marketed and pipeline asthma/COPD products in Australia, examining both clinical and commercial factors driving product differentiation and uptake.

Published By Datamonitor
20 May 2010 $5700
Buy
Report
Report

Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity

This report analyzes three emerging markets, Brazil, Russia and India as targets for HIV drug manufacturers. It discusses the commercial and regulatory environment, guidelines, domestic and multinational competition as well as market entry strategies.

Published By Datamonitor
25 May 2010 $3800
Buy
Report
Report

Stakeholder Opinions: Melanoma - Future treatment will be based on individual tumor gene expression signatures

Key issues in the melanoma market including forecast epidemiology data, current treatment patterns and controversies, unmet needs, insight into late-phase pipeline drugs and key stakeholder opinions.

Published By Datamonitor
31 May 2010 $3800
Buy
Report
Report

Stakeholder Opinions: Hemophilia - The harsh reality of commercialising a great research opportunity?

The hemophilia patient population is small, but costs of care for this patient group are a major burden for both developed and developing markets, a burden expected to grow as life expectancies rise and more sufferers demand access to therapeutics.

Published By Datamonitor
03 Jun 2010 $3800
Buy
Report
Report

UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth

Overview of the UK pharmaceutical market including socioeconomic and demographic trends, regulatory issues, generics and biosimilars analysis and pharmaceutical company infrastructure analysis.

Published By Datamonitor
14 Jun 2010 $11400
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.